Withholding Proven Treatment in Clinical Research
- 20 September 2001
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 345 (12) , 912-914
- https://doi.org/10.1056/nejm200109203451210
Abstract
The use of placebo-controlled trials began just before World War II, and the Declaration of Helsinki, which arose from the Nuremberg Code, was formulated after the war. Placebo-controlled studies soon became the gold standard of evidence, and the Declaration of Helsinki became the gold standard of research ethics. However, the practices of the first collided with the principles of the second, and researchers and ethicists have been trying to resolve this problem ever since. The debate over placebo-controlled trials is implicitly and inextricably linked to concern about withholding treatment — specifically, withholding proven or standard treatment — in the course . . .Keywords
This publication has 9 references indexed in Scilit:
- The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 DiabetesNew England Journal of Medicine, 2001
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- The Ethics of Placebo-Controlled Trials — A Middle GroundNew England Journal of Medicine, 2001
- Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized TrialAnnals of Internal Medicine, 2001
- War crimes and medical scienceBMJ, 1996
- Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis.Hypertension, 1993
- Long-Term Stabilizing Effect of Angiotensin-Converting Enzyme Inhibition on Plasma Creatinine and on Proteinuria in Normotensive Type II Diabetic PatientsAnnals of Internal Medicine, 1993
- Mortality in non‐consenters in a post‐myocardial infarction trialJournal of Internal Medicine, 1990